VIP and Miscarriage: Treatment with vasoactive intestinal peptide (VIP) in a miscarriage-prone mouse model (CBA/J×DBA/2) can regulate the endocytosis of maternal macrophages and promote the expression of TGF-β1 at the implantation site of the mouse, significantly increasing the number of implant points (97).